聯邦制藥(03933.HK)旗下利拉魯(月太)注射液糖尿病適應症上市申請獲受理
聯邦制藥(03933.HK)公布,全資附屬珠海聯邦生物醫藥關於利拉魯(月太)注射液糖尿病適應症的上市申請,於上日(22日)獲得國家藥監局受理。
利拉魯(月太)是一種人胰高血糖素樣(月太)-1類似物,用於成人2型糖尿病的治療,一天註射一次即可滿足患者的降糖需求。GLP-1類似物能夠有效地控制血糖,減少低血糖風險,同時兼具減肥和心血管獲益等功效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.